Role of Whole-Body 18F-FDG PET/CT in Screening for Metastases in Newly Diagnosed Sinonasal Malignancies

2019 ◽  
Vol 212 (6) ◽  
pp. 1327-1334
Author(s):  
Kerem Ozturk ◽  
Mehmet Gencturk ◽  
Matthew Rischall ◽  
Emiro Caicedo-Granados ◽  
Faqian Li ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Whole Body ◽  
Newly Diagnosed ◽  
Sinonasal Malignancies ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Performance of whole-body 18F-FDG PET/CT as a posttreatment surveillance tool for sinonasal malignancies

2019 ◽  
Vol 276 (3) ◽  
pp. 847-855 ◽  
Author(s):  
Kerem Ozturk ◽  
Mehmet Gencturk ◽  
Emiro Caicedo-Granados ◽  
Faqian Li ◽  
Zuzan Cayci
Keyword(s):  
Fdg Pet ◽  
Whole Body ◽  
Sinonasal Malignancies ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Appropriate timing of surveillance intervals with whole-body 18F-FDG PET/CT following treatment for sinonasal malignancies

2019 ◽  
Vol 118 ◽  
pp. 75-80
Author(s):  
Kerem Ozturk ◽  
Mehmet Gencturk ◽  
Emiro Caicedo-Granados ◽  
Faqian Li ◽  
Zuzan Cayci
Keyword(s):  
Fdg Pet ◽  
Whole Body ◽  
Sinonasal Malignancies ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1019
Author(s):  
Christos Sachpekidis ◽  
Jessica C. Hassel ◽  
Annette Kopp-Schneider ◽  
Uwe Haberkorn ◽  
Antonia Dimitrakopoulou-Strauss
Keyword(s):  
Metastatic Melanoma ◽  
Fdg Pet ◽  
Whole Body ◽  
Conventional Imaging ◽  
Interim Pet ◽  
Pet Ct ◽  
Predictive Role ◽  
18F Fdg ◽  
Fdg Pet Ct

The advent of novel immune checkpoint inhibitors has led to unprecedented survival rates in advanced melanoma. At the same time, it has raised relevant challenges in the interpretation of treatment response by conventional imaging approaches. In the present prospective study, we explored the predictive role of quantitative, dynamic 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) performed early during immunotherapy in metastatic melanoma patients receiving treatment with programmed cell death protein 1 (PD-1) inhibitors. Twenty-five patients under PD-1 blockade underwent dynamic and static 18F-FDG PET/CT before the start of treatment (baseline PET/CT) and after the initial two cycles of therapy (interim PET/CT). The impact of semiquantitatively (standardized uptake value, SUV) and quantitatively (based on compartment modeling and fractal analysis) derived PET/CT parameters, both from melanoma lesions and different reference tissues, on progression-free survival (PFS) was analyzed. At a median follow-up of 24.2 months, survival analysis revealed that the interim PET/CT parameters SUVmean, SUVmax and fractal dimension (FD) of the hottest melanoma lesions adversely affected PFS, while the parameters FD of the thyroid, as well as SUVmax and k3 of the bone marrow positively affected PFS. The herein presented findings highlight the potential predictive role of quantitative, dynamic, interim PET/CT in metastatic melanoma under PD-1 blockade. Therefore, dynamic PET/CT could be performed in selected oncological cases in combination with static, whole-body PET/CT in order to enhance the diagnostic certainty offered by conventional imaging and yield additional information regarding specific molecular and pathophysiological mechanisms involved in tumor biology and response to treatment.

Newly Diagnosed Lymphoma: Initial Results With Whole-Body T1-Weighted, STIR, and Diffusion-Weighted MRI Compared With 18F-FDG PET/CT

2011 ◽  
Vol 196 (3) ◽  
pp. 662-669 ◽  
Author(s):  
Henriëtte M. E. Quarles van Ufford ◽  
Thomas C. Kwee ◽  
Frederik J. Beek ◽  
Maarten S. van Leeuwen ◽  
Taro Takahara ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Whole Body ◽  
Newly Diagnosed ◽  
Diffusion Weighted Mri ◽  
Diffusion Weighted ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
And Diffusion ◽  
Initial Results

Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results

2006 ◽  
Vol 33 (5) ◽  
pp. 525-531 ◽  
Author(s):  
Cristina Nanni ◽  
Elena Zamagni ◽  
Mohsen Farsad ◽  
Paolo Castellucci ◽  
Patrizia Tosi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Fdg Pet ◽  
Bone Involvement ◽  
Newly Diagnosed ◽  
Preliminary Results ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals The Role of 18F-FDG-PET/CT Scan in the Management of Multiple Myeloma

2020 ◽  
Vol 5 (2) ◽  
pp. 119-123
Author(s):  
Shirin Haghighat
Keyword(s):  
Multiple Myeloma ◽  
Ct Scan ◽  
Fdg Pet ◽  
Bone Involvement ◽  
Whole Body ◽  
Newly Diagnosed ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Pet Ct Scan

Bone lesion is a myeloma-defining event which is reported in 80% of multiple myeloma patients. Imaging of bone is essential in the evaluation of pattern and extent of bone involvement. Recently, whole body X ray (WBXR) has been replaced by more accurate imaging such as whole bode MRI and FDG-PET/CT scan. This review article provides the advantages and role of PET/CT scan in the diagnosis and management of multiple myeloma patients. Generally, PET/CT in diagnosis of bone involvement of newly diagnosed myeloma patients is more sensitive than WBXR. The prognostic value of PET/CT in newly diagnosed patients has been described as well. Different studies have demonstrated that several PET parameters such as the number of focal lesions (FL), SUVmax and extramedullary disease(EMD) may affect the outcome of multiple myeloma patients. Interstingely, the main role of PET/CT in myeloma patients is treatment response monitoring and to some extent assessment of MRD. PET/CT appears to be superior than MRI in evaluation of response due to its ability in differentiating active lesion from negative one.

scholarly journals Prognostic Role of 2-[18F]FDG PET/CT Metabolic Volume Parameters in Patients Affected by Differentiated Thyroid Carcinoma with High Thyroglobulin Level, Negative 131I WBS and Positive 2-[18F]-FDG PET/CT

Diagnostics ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 2189
Author(s):  
Domenico Albano ◽  
Francesco Dondi ◽  
Angelica Mazzoletti ◽  
Pietro Bellini ◽  
Carlo Rodella ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Fdg Pet ◽  
Differentiated Thyroid Carcinoma ◽  
Whole Body ◽  
Prognostic Role ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Metabolic Volume

The clinical and prognostic role of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography (2-[18F]FDG PET/CT) in the study of patients affected by differentiated thyroid carcinoma (DTC) with positive serum thyroglobulin (Tg) level and negative [131I] whole-body scan ([131I]WBS) has already been demonstrated. However, the potential prognostic role of semi-quantitative PET metabolic volume features, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG), has not yet been clearly investigated. The aim of this retrospective study was to investigate whether the main metabolic PET/CT parameters may predict the prognosis. We retrospectively included 122 patients with a positive 2-[18F]FDG PET/CT for DTC disease after a negative [131I]WBS with Tg > 10 ng/mL. The maximum and mean standardized uptake value (SUVmax and SUVmean), MTV and TLG of the hypermetabolic lesion, total MTV (tMTV) and total TLG (tTLG) were measured for each scan. Progression-free survival (PFS) and overall survival (OS) curves were plotted according to the Kaplan–Meier analysis. After a median follow up of 53 months, relapse/progression of disease occurred in 87 patients and death in 42. The median PFS and OS were 19 months (range 1–132 months) and 46 months (range 1–145 months). tMTV and tTLG were the only independent prognostic factors for OS. No variables were significantly correlated with PFS. The best thresholds derived in our sample were 6.6 cm3 for MTV and 119.4 for TLG. In patients with negative WBS and Tg > 10 ng/mL, 2-[18F]FDG PET/CT metabolic volume parameters (tMTV and tTLG) may help to predict OS.

scholarly journals Whole-body magnetic resonance/diffusion-weighted sequence with background signal suppression (WB-MR/DWIBS) vs. 18F-FDG PET/CT in diagnosis of lymphoma

2020 ◽  
Vol 51 (1) ◽  
Author(s):  
Gihan Hassan Gamal
Keyword(s):  
Fdg Pet ◽  
Lesion Detection ◽  
Whole Body ◽  
Reference Standard ◽  
Background Signal ◽  
Signal Suppression ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Abstract Background The purpose of this study was to compare the performance of whole-body magnetic resonance/diffusion-weighted imaging with background signal suppression (WB-MR/DWIBS) method, with that of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT), for lesion detection and initial staging of patients with lymphoma using the histopathologically diagnosis as a reference standard. Results Thirty-two patients with newly pathologically proven lymphoma were enrolled in this prospective study from May 2018 to January 2020 (27 males, 5 females). All patients underwent PET/CT followed by WB-MR/DWIBS as an attempt to compare the performance of both methods for lesion detection and initial staging in patients with lymphoma. The overall sensitivity, specificity, PPV, NPV, and accuracy of 18F-FDG-PET/CT vs WB-MR/DWIBS in correlation with reference standard data in detection of lymphoma were calculated for PET/CT 96%, 100%, 100%, 80%, and 97% while those of WB-MR/DWIBS were 93%, 76%, 96%, 61%, and 91%, respectively. Conclusion 18F-FDG PET/CT remains the standard reference of imaging in evaluation of lymphoma due to its higher sensitivity and specificity over WB-MR/DWIBS. Future studies with larger cohorts are necessary for better evaluation of the role of WB-MR/DWIBS in lymphoma patients. The current study highlights the potential complementary role of WB-MRI/DWIBS in the context of bone marrow involvement evaluation omitting unnecessary bone marrow biopsy.

Sign in / Sign up

Export Citation Format

Share Document